Articles related to CHEMOTHERAPY

Mirvetuximab soravtansine generated an objective response in nearly 1/3 of patients participating. That compares with response rates in the single digits for current treatments in patients whose ovarian cancer doesn’t respond to platinum-based chemotherapy.

The phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy significantly improved OS compared to chemotherapy alone in patients with previously untreated advanced esophageal squamous cell carcinoma.

In this updated analysis of the KEYNOTE-177 study, although pembrolizumab continued to show durable antitumor activity and fewer treatment-related adverse events compared with chemotherapy, there was no significant difference in overall survival between the two treatment groups.

Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) might be used to identify patients who would benefit more from standard-of-care adjuvant chemotherapy by accurately assessing recurrence-risk post-surgery and by evaluating adjuvant chemotherapy efficacy. This analysis from the GALAXY study, an observational study monitoring MRD, evaluates the association of ctDNA dynamics with a short-term clinical outcome and ACT efficacy.

A literature review involving 24 recent studies yielded an update to ASCO’s recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer.

An 87-year-old white man presented to a hospital emergency surgical department with two round, grayish-brown nodules on his abdomen. He had no other complaints except feeling tired and dizzy for the last few months. He had a 120 pack-year smoking history but was not taking any medications and had not experienced a cough, chest pain, shortness of breath, or other breathing problems.